<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="../../../current/spl_canada.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="urn:hl7-org:v3 https://raw.githubusercontent.com/HealthCanada/HPFB/master/Structured-Product-Labeling-(SPL)/Schema/current/SPL.xsd">
  <templateId extension="NDS" root="2.16.840.1.113883.2.20.6.37"/>
  <id root="df363dae-0612-4be7-bb92-a8381fa1da35"/>
  <code code="5" codeSystem="2.16.840.1.113883.2.20.6.10"
    displayName="2016 PRODUCT MONOGRAPH TEMPLATE - SCHEDULE D - BIOSIMILAR BIOLOGIC DRUG"/>
  <title><sup>Pr</sup>HADLIMA<sup>TM</sup><br/><br/> Adalimumab injection<br/><br/> 40 mg in 0.8 mL
    sterile solution (50 mg/mL), pre-filled syringe for subcutaneous injection<br/><br/>
    <sup>Pr</sup>HADLIMA<sup>TM</sup><br/><br/> Adalimumab injection<br/><br/> 40 mg in 0.8 mL
    sterile solution (50 mg/mL), auto-injector for subcutaneous injection<br/><br/><br/> Biological
    Response Modifier <br/><br/><br/> HADLIMA<sup>TM</sup> or HADLIMA<sup>TM</sup>
      PushTouch<sup>TM</sup> (adalimumab injection) treatment should be initiated and supervised by
    specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis,
    polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult
    Crohn’s disease, ulcerative colitis, adult hidradenitis suppurativa, plaque psoriasis or adult
    uveitis, and familiar with the HADLIMA<sup>TM</sup> or HADLIMA<sup>TM</sup>
      PushTouch<sup>TM</sup> efficacy and safety profile. </title>
  <effectiveTime>
    <originalText description="Date of Initial Approval">20190313</originalText>
  </effectiveTime>
  <languageCode code="1" codeSystem="2.16.840.1.113883.2.20.6.29" displayName="ENGLISH"/>
  <setId root="deb4ec67-8764-4b72-b7a5-0bae88db11a3"/>
  <versionNumber value="1"/>
  <author>
    <!--Organization Information-->
    <time/>
    <assignedEntity>
      <representedOrganization>
        <!--Market Authorization Holder-->
        <id extension="1111" root="2.16.840.1.113883.2.20.6.31"/>
        <name>SAMSUNG BIOEPIS</name>
        <contactParty>
          <addr>
            <streetAddressLine>107 Cheomdan-daero</streetAddressLine>
            <city>Yeonsu-gu</city>
            <state>Incheon</state>
            <postalCode>21987</postalCode>
            <country code="KOR" codeSystem="2.16.840.1.113883.2.20.6.17"
              displayName="REPUBLIC OF KOREA"/>
          </addr>
          <telecom value="tel:+12345678910"/>
          <telecom value="mailto:test@canada.ca"/>
          <telecom value="https://:www.test.ca"/>
          <contactPerson/>
        </contactParty>
        <assignedEntity>
          <assignedOrganization>
            <!-- Importer/Distributor -->
            <id extension="0000" root="2.16.840.1.113883.2.20.6.31"/>
            <name>Merck Canada Inc.</name>
            <contactParty>
              <addr>
                <streetAddressLine>Street address#2</streetAddressLine>
                <city>Kirkland</city>
                <state>Quebec</state>
                <postalCode>H9H 4M7</postalCode>
                <country code="CAN" codeSystem="2.16.840.1.113883.2.20.6.17" displayName="CANADA"/>
              </addr>
              <telecom value="tel:+15678929988"/>
              <telecom value="mailto:test.2@canada.ca"/>
              <telecom value="https://www.test.ca"/>
              <contactPerson/>
            </contactParty>
          </assignedOrganization>
        </assignedEntity>
      </representedOrganization>
    </assignedEntity>
  </author>
  <component>
    <structuredBody>
      <component>
        <!-- Manufactured Product Information -->
        <section ID="f6ac9de5-be91-442c-9579-5bc9ebd36902">
          <id root="bdeefc11-4315-41e3-8c56-83e8bf4f770b"/>
          <code code="MP" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="MANUFACTURED PRODUCT"/>
          <effectiveTime value="20190313"/>
          <subject>
            <manufacturedProduct>
              <manufacturedProduct>
                <code code="123456" codeSystem="2.16.840.1.113883.2.20.6.42"/>
                <!-- DIN Number -->
                <name>HADLIMA PUSHTOUCH</name>
                <formCode code="xx" codeSystem="2.16.840.1.113883.2.20.6.3"
                  displayName="SOLUTION FOR INJECTION"/>
                <asEntityWithGeneric>
                  <genericMedicine>
                    <name>ADALIMUMAB</name>
                  </genericMedicine>
                </asEntityWithGeneric>
                <ingredient classCode="ACTIB">
                  <quantity>
                    <numerator value="50" unit="mg"/>
                    <denominator value="1" unit="mL"/>
                  </quantity>
                  <ingredientSubstance>
                    <code code="FYS6T7F842" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="ADALIMUMAB"/>
                    <name>ADALIMUMAB</name>
                    <activeMoiety>
                      <activeMoiety>
                        <code code="FYS6T7F842" codeSystem="2.16.840.1.113883.2.20.6.14"
                          displayName="ingredient#2"/>
                        <name>ADALIMUMAB</name>
                      </activeMoiety>
                    </activeMoiety>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="CITRIC ACID MONOHYDRATE"/>
                    <name>CITRIC ACID MONOHYDRATE</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="B22547B95K" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="TRISODIUM CITRATE DIHYDRATE"/>
                    <name>TRISODIUM CITRATE DIHYDRATE</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="4QD397987E" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="HISTIDINE"/>
                    <name>HISTIDINE</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="X573657P6P" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE"/>
                    <name>HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="506T60A25R" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="SORBITOL"/>
                    <name>SORBITOL</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="POLYSORBATE 20"/>
                    <name>POLYSORBATE 20</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="WATER"/>
                    <name>WATER</name>
                  </ingredientSubstance>
                </ingredient>
                <asContent>
                  <!-- Packaging -->
                  <quantity>
                    <numerator value="1" unit="mL"/>
                    <denominator value="1"/>
                  </quantity>
                  <containerPackagedProduct>
                    <code code="ABC-1234" codeSystem="2.16.840.1.113883.2.20.6.56"/>
                    <!--company defined pack code-->
                    <formCode code="30051000" codeSystem="2.16.840.1.113883.2.20.6.32"
                      displayName="PRE-FILLED PEN"/>
                    <asContent>
                      <!-- Packaging -->
                      <quantity>
                        <numerator value="2" unit="1"/>
                        <denominator value="1"/>
                      </quantity>
                      <containerPackagedProduct>
                        <code code="ABC-1234" codeSystem="2.16.840.1.113883.2.20.6.56"/>
                        <!--company defined pack code-->
                        <formCode code="xx" codeSystem="2.16.840.1.113883.2.20.6.32"
                          displayName="CARTON"/>
                      </containerPackagedProduct>
                      <subjectOf>
                        <marketingAct>
                          <code code="1" codeSystem="2.16.840.1.113883.2.20.6.11"
                            displayName="APPROVED"/>
                          <statusCode code="ACTIVE"/>
                          <effectiveTime>
                            <!-- regulatory status of this package -->
                            <low value="20190313"/>
                          </effectiveTime>
                        </marketingAct>
                      </subjectOf>
                    </asContent>
                  </containerPackagedProduct>
                </asContent>
              </manufacturedProduct>
              <subjectOf>
                <!--Regulatory Activity associated with this products status-->
                <approval>
                  <id extension="222615" root="2.16.840.1.113883.2.20.6.49"/>
                  <!-- Control Number -->
                  <code code="1" codeSystem="2.16.840.1.113883.2.20.6.37" displayName="NDS"/>
                  <author>
                    <territorialAuthority>
                      <territory>
                        <code code="CAN" codeSystem="2.16.840.1.113883.2.20.6.17"
                          displayName="CANADA"/>
                      </territory>
                    </territorialAuthority>
                  </author>
                </approval>
              </subjectOf>
              <subjectOf>
                <!--Regulatory status of this product-->
                <marketingAct>
                  <code code="1" codeSystem="2.16.840.1.113883.2.20.6.11" displayName="APPROVED"/>
                  <statusCode code="ACTIVE"/>
                  <effectiveTime>
                    <low value="20190313"/>
                    <!-- Date of initial approval. Include high value=yyyymmdd if cancelled -->
                  </effectiveTime>
                </marketingAct>
              </subjectOf>
              <!--Characteristics of this product-->
              <subjectOf>
                <characteristic>
                  <code code="1" codeSystem="2.16.840.1.113883.2.20.6.23" displayName="PRODUCT TYPE"/>
                  <value code="2" codeSystem="2.16.840.1.113883.2.20.6.53" displayName="BIOLOGIC"
                    xsi:type="CV">
                    <originalText>BIOLOGIC</originalText>
                  </value>
                </characteristic>
              </subjectOf>
              <subjectOf>
                <characteristic>
                  <code code="2" codeSystem="2.16.840.1.113883.2.20.6.23" displayName="COLOUR"/>
                  <value code="xx" codeSystem="2.16.840.1.113883.2.20.6.24" displayName="CLEAR"
                    xsi:type="CV">
                    <originalText>Colourless</originalText>
                  </value>
                </characteristic>
              </subjectOf>
              <subjectOf>
                <characteristic>
                  <code code="9" codeSystem="2.16.840.1.113883.2.20.6.23"
                    displayName="PHARMACEUTICAL STANDARD"/>
                  <value code="7" codeSystem="2.16.840.1.113883.2.20.6.5" displayName="USP"
                    xsi:type="CV"/>
                </characteristic>
              </subjectOf>
              <subjectOf>
                <characteristic>
                  <code code="10" codeSystem="2.16.840.1.113883.2.20.6.23" displayName="SCHEDULE"/>
                  <value code="1" codeSystem="2.16.840.1.113883.2.20.6.2" displayName="PRESCRIPTION"
                    xsi:type="CV"/>
                </characteristic>
              </subjectOf>
              <subjectOf>
                <characteristic>
                  <code code="11" codeSystem="2.16.840.1.113883.2.20.6.23"
                    displayName="THERAPEUTIC CLASS"/>
                  <value code="1" codeSystem="2.16.840.1.113883.2.20.6.6"
                    displayName="DISEASE-MODIFYING ANTIRHEUMATIC AGENTS" xsi:type="CV"/>
                </characteristic>
              </subjectOf>
              <consumedIn>
                <substanceAdministration>
                  <routeCode code="20066000" codeSystem="2.16.840.1.113883.2.20.6.7"
                    displayName="SUBCUTANEOUS USE"/>
                </substanceAdministration>
              </consumedIn>
            </manufacturedProduct>
          </subject>
          <subject>
            <manufacturedProduct>
              <manufacturedProduct>
                <code code="123456" codeSystem="2.16.840.1.113883.2.20.6.42"/>
                <!-- DIN Number -->
                <name>HADLIMA</name>
                <formCode code="xx" codeSystem="2.16.840.1.113883.2.20.6.3"
                  displayName="SOLUTION FOR INJECTION"/>
                <asEntityWithGeneric>
                  <genericMedicine>
                    <name>ADALIMUMAB</name>
                  </genericMedicine>
                </asEntityWithGeneric>
                <ingredient classCode="ACTIB">
                  <quantity>
                    <numerator value="50" unit="mg"/>
                    <denominator value="1" unit="mL"/>
                  </quantity>
                  <ingredientSubstance>
                    <code code="FYS6T7F842" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="ADALIMUMAB"/>
                    <name>ADALIMUMAB</name>
                    <activeMoiety>
                      <activeMoiety>
                        <code code="FYS6T7F842" codeSystem="2.16.840.1.113883.2.20.6.14"
                          displayName="ingredient#2"/>
                        <name>ADALIMUMAB</name>
                      </activeMoiety>
                    </activeMoiety>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="CITRIC ACID MONOHYDRATE"/>
                    <name>CITRIC ACID MONOHYDRATE</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="B22547B95K" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="TRISODIUM CITRATE DIHYDRATE"/>
                    <name>TRISODIUM CITRATE DIHYDRATE</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="4QD397987E" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="HISTIDINE"/>
                    <name>HISTIDINE</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="X573657P6P" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE"/>
                    <name>HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="506T60A25R" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="SORBITOL"/>
                    <name>SORBITOL</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="POLYSORBATE 20"/>
                    <name>POLYSORBATE 20</name>
                  </ingredientSubstance>
                </ingredient>
                <ingredient classCode="IACT">
                  <ingredientSubstance>
                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.2.20.6.14"
                      displayName="WATER"/>
                    <name>WATER</name>
                  </ingredientSubstance>
                </ingredient>
                <asContent>
                  <!-- Packaging -->
                  <quantity>
                    <numerator value="1" unit="mL"/>
                    <denominator value="1"/>
                  </quantity>
                  <containerPackagedProduct>
                    <code code="ABC-1234" codeSystem="2.16.840.1.113883.2.20.6.56"/>
                    <!--company defined pack code-->
                    <formCode code="30051000" codeSystem="2.16.840.1.113883.2.20.6.32"
                      displayName="PRE-FILLED SYRINGE"/>
                    <asContent>
                      <!-- Packaging -->
                      <quantity>
                        <numerator value="2" unit="1"/>
                        <denominator value="1"/>
                      </quantity>
                      <containerPackagedProduct>
                        <code code="ABC-1234" codeSystem="2.16.840.1.113883.2.20.6.56"/>
                        <!--company defined pack code-->
                        <formCode code="xx" codeSystem="2.16.840.1.113883.2.20.6.32"
                          displayName="CARTON"/>
                      </containerPackagedProduct>
                      <subjectOf>
                        <marketingAct>
                          <code code="1" codeSystem="2.16.840.1.113883.2.20.6.11"
                            displayName="APPROVED"/>
                          <statusCode code="ACTIVE"/>
                          <effectiveTime>
                            <!-- regulatory status of this package -->
                            <low value="20190313"/>
                          </effectiveTime>
                        </marketingAct>
                      </subjectOf>
                    </asContent>
                  </containerPackagedProduct>
                </asContent>
              </manufacturedProduct>
              <subjectOf>
                <!--Regulatory Activity associated with this products status-->
                <approval>
                  <id extension="222615" root="2.16.840.1.113883.2.20.6.49"/>
                  <!-- Control Number -->
                  <code code="1" codeSystem="2.16.840.1.113883.2.20.6.37" displayName="NDS"/>
                  <author>
                    <territorialAuthority>
                      <territory>
                        <code code="CAN" codeSystem="2.16.840.1.113883.2.20.6.17"
                          displayName="CANADA"/>
                      </territory>
                    </territorialAuthority>
                  </author>
                </approval>
              </subjectOf>
              <subjectOf>
                <!--Regulatory status of this product-->
                <marketingAct>
                  <code code="1" codeSystem="2.16.840.1.113883.2.20.6.11" displayName="APPROVED"/>
                  <statusCode code="ACTIVE"/>
                  <effectiveTime>
                    <low value="20190313"/>
                    <!-- Date of initial approval. Include high value=yyyymmdd if cancelled -->
                  </effectiveTime>
                </marketingAct>
              </subjectOf>
              <!--Characteristics of this product-->
              <subjectOf>
                <characteristic>
                  <code code="1" codeSystem="2.16.840.1.113883.2.20.6.23" displayName="PRODUCT TYPE"/>
                  <value code="2" codeSystem="2.16.840.1.113883.2.20.6.53" displayName="BIOLOGIC"
                    xsi:type="CV">
                    <originalText>BIOLOGIC</originalText>
                  </value>
                </characteristic>
              </subjectOf>
              <subjectOf>
                <characteristic>
                  <code code="2" codeSystem="2.16.840.1.113883.2.20.6.23" displayName="COLOUR"/>
                  <value code="xx" codeSystem="2.16.840.1.113883.2.20.6.24" displayName="CLEAR"
                    xsi:type="CV">
                    <originalText>Colourless</originalText>
                  </value>
                </characteristic>
              </subjectOf>
              <subjectOf>
                <characteristic>
                  <code code="9" codeSystem="2.16.840.1.113883.2.20.6.23"
                    displayName="PHARMACEUTICAL STANDARD"/>
                  <value code="7" codeSystem="2.16.840.1.113883.2.20.6.5" displayName="USP"
                    xsi:type="CV"/>
                </characteristic>
              </subjectOf>
              <subjectOf>
                <characteristic>
                  <code code="10" codeSystem="2.16.840.1.113883.2.20.6.23" displayName="SCHEDULE"/>
                  <value code="1" codeSystem="2.16.840.1.113883.2.20.6.2" displayName="PRESCRIPTION"
                    xsi:type="CV"/>
                </characteristic>
              </subjectOf>
              <subjectOf>
                <characteristic>
                  <code code="11" codeSystem="2.16.840.1.113883.2.20.6.23"
                    displayName="THERAPEUTIC CLASS"/>
                  <value code="1" codeSystem="2.16.840.1.113883.2.20.6.6"
                    displayName="DISEASE-MODIFYING ANTIRHEUMATIC AGENTS" xsi:type="CV"/>
                </characteristic>
              </subjectOf>
              <consumedIn>
                <substanceAdministration>
                  <routeCode code="20066000" codeSystem="2.16.840.1.113883.2.20.6.7"
                    displayName="SUBCUTANEOUS USE"/>
                </substanceAdministration>
              </consumedIn>
            </manufacturedProduct>
          </subject>
        </section>
      </component>
      <component>
        <!--Title Page section-->
        <section ID="cd8d3086-e343-48f4-9cec-524834b3803b">
          <id root="eed00b53-cdb2-4aa6-9e82-88b7d793b208"/>
          <code code="TP" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="TITLE PAGE"/>
          <title>TITLE PAGE</title>
          <effectiveTime value="20190313"/>
          <component>
            <section ID="be75cfb9-3131-4903-800b-267427388a13">
              <id root="b9db4be0-3146-437a-bd7b-4a3e010adaad"/>
              <code code="TP-1.1" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="TITLE"/>
              <title>TITLE</title>
              <text>
                <paragraph><sup>Pr</sup>HADLIMA<sup>TM</sup><br/><br/> Adalimumab
                  injection<br/><br/> 40 mg in 0.8 mL sterile solution (50 mg/mL), pre-filled
                  syringe for subcutaneous injection<br/><br/>
                  <sup>Pr</sup>HADLIMA<sup>TM</sup><br/><br/> Adalimumab injection<br/><br/> 40 mg
                  in 0.8 mL sterile solution (50 mg/mL), auto-injector for subcutaneous
                  injection<br/><br/><br/> HADLIMA<sup>TM</sup> (adalimumab injection) is a
                  biosimilar biologic drug (biosimilar) to Humira®.<br/><br/> Biological Response
                  Modifier <br/><br/><br/>
                  <content styleCode="bold">HADLIMA<sup>TM</sup> or HADLIMA<sup>TM</sup>
                      PushTouch<sup>TM</sup> (adalimumab injection) treatment should be initiated
                    and supervised by specialist physicians experienced in the diagnosis and
                    treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis,
                    psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative
                    colitis, adult hidradenitis suppurativa, plaque psoriasis or adult uveitis, and
                    familiar with the HADLIMA<sup>TM</sup> or HADLIMA<sup>TM</sup>
                      PushTouch<sup>TM</sup> efficacy and safety profile. </content></paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="f187daf9-5e75-425a-9de6-f6ce1af2a965">
              <id root="ac26f58c-721a-4c51-8bbc-c9dddb1f1233"/>
              <code code="TP-1.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="COMPANY NAME AND ADDRESS"/>
              <title>COMPANY NAME AND ADDRESS</title>
              <text>
                <paragraph>SAMSUNG BIOEPIS<br/> 107, Cheomdan-daero, Yeonsu-gu, Incheon, 21987,<br/>
                  Republic of Korea<br/><br/> Distributed by:<br/> Merck Canada Inc.<br/> Kirkland
                  QC Canada H9H 4M7 </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="bf2dab4e-fd04-4ec9-9cdc-247188622d0f">
              <id root="b5f1dea3-d907-4664-b46f-e1d9736d47af"/>
              <code code="TP-1.3" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="DATE OF INITIAL APPROVAL"/>
              <title>DATE OF INITIAL APPROVAL</title>
              <text>
                <paragraph>20190313</paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="ebc3f3dc-71be-424f-91ef-8aca8c138b21">
              <id root="efd8c4c1-d0dd-434d-b1c2-4daa18752fa8"/>
              <code code="TP-1.5" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="CONTROL NUMBER"/>
              <title>CONTROL NUMBER</title>
              <text>
                <paragraph>222615</paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
        </section>
      </component>
      <component>
        <!-- PART I: HEALTH PROFESSIONAL INFORMATION -->
        <section ID="a16a94eb-e2be-45c0-8b2e-15d0d0eebea8">
          <id root="e6bb83b9-2602-4f96-9077-b8b9535c254e"/>
          <code code="P1" codeSystem="2.16.840.1.113883.2.20.6.65"
            displayName="PART I: HEALTH PROFESSIONAL INFORMATION"/>
          <title>PART I: HEALTH PROFESSIONAL INFORMATION</title>
          <effectiveTime value="20190313"/>
          <component>
            <section ID="c2ea4fad-2b79-4dbc-8d99-6843adc2dec8">
              <id root="9a3f869a-7734-425a-85d8-b8bd4d3500a5"/>
              <code code="P1-1" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="1 INDICATIONS"/>
              <title>1 INDICATIONS</title>
              <text>
                <paragraph>Indications have been granted on the basis of similarity between
                    HADLIMA<sup>TM</sup> and the reference biologic drug Humira®.<br/><br/>
                  <content styleCode="bold">HADLIMA<sup>TM</sup> or HADLIMA<sup>TM</sup>
                      PushTouch<sup>TM</sup> (adalimumab injection) treatment should be initiated
                    and supervised by specialist physicians experienced in the diagnosis and
                    treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic
                    arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult
                    Crohn’s disease (CD), ulcerative colitis (UC), adult hidradenitis suppurativa
                    (HS), plaque psoriasis or adult uveitis, and familiar with the
                      HADLIMA<sup>TM</sup> or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup> efficacy
                    and safety profile.</content><br/><br/> HADLIMA<sup>TM</sup> (adalimumab
                  injection in pre-filled syringe) and HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>
                  (adalimumab injection in auto-injector) are indicated for:<br/><br/>
                  <content styleCode="bold"><content styleCode="underline">Rheumatoid
                      Arthritis</content></content></paragraph><br/>
                <list listType="unordered">
                  <item>reducing the signs and symptoms, inducing major clinical response and
                    clinical remission, inhibiting the progression of structural damage and
                    improving physical function in adult patients with moderately to severely active
                    rheumatoid arthritis. HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                      PushTouch<sup>TM</sup>) can be used alone or in combination with methotrexate
                    (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs).</item>
                </list>
                <paragraph> When used as first-line treatment in recently diagnosed patients who
                  have not been previously treated with MTX, HADLIMA<sup>TM</sup> (or
                    HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) should be given in combination with
                  methotrexate.<br/> HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                    PushTouch<sup>TM</sup>) can be given as monotherapy in case of intolerance to
                  methotrexate or when treatment with MTX is contraindicated.<br/><br/>
                  <content styleCode="bold"><content styleCode="underline">Polyarticular Juvenile
                      Idiopathic Arthritis</content></content>
                </paragraph><br/>
                <list listType="unordered">
                  <item>in combination with MTX, reducing signs and symptoms of moderately to
                    severely active polyarticular juvenile idiopathic arthritis in patients, 4 years
                    of age and older, who have had an inadequate response to one or more
                    disease-modifying anti-rheumatic drugs (DMARDs). HADLIMA<sup>TM</sup> (or
                      HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) can be used as monotherapy in
                    case of intolerance to methotrexate or when continued treatment with
                    methotrexate is not appropriate (see <content styleCode="bold">CLINICAL TRIALS –
                      REFERENCE BIOLOGIC DRUG, Pediatric</content>, <content styleCode="underline"
                      >Polyarticular Juvenile Idiopathic Arthritis</content>, <content
                      styleCode="bold"><content styleCode="underline">Study
                      Results</content></content>). Adalimumab injection has not been studied in
                    pediatric patients with polyarticular juvenile idiopathic arthritis aged less
                    than 2 years. </item>
                  <item>HADLIMA<sup>TM</sup> and HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup> are
                    available for pediatric polyarticular juvenile idiopathic arthritis patients who
                    require the full 40 mg dosage based on body weight and height (See <content
                      styleCode="bold">DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage
                      Adjustment, Pediatrics</content>, <content styleCode="underline">Polyarticular
                      Juvenile Idiopathic Arthritis</content>). </item>
                </list>
                <paragraph>
                  <content styleCode="bold"><content styleCode="underline">Psoriatic
                      Arthritis</content></content>
                </paragraph><br/>
                <list>
                  <item>reducing the signs and symptoms of active arthritis and inhibiting the
                    progression of structural damage and improving the physical function in adult
                    psoriatic arthritis patients. HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                      PushTouch<sup>TM</sup>) can be used in combination with methotrexate (MTX) in
                    patients who do not respond adequately to methotrexate alone.</item>
                </list>
                <paragraph><content styleCode="bold"><content styleCode="underline">Ankylosing
                      Spondylitis</content></content></paragraph><br/>
                <list listType="unordered">
                  <item>reducing signs and symptoms in patients with active ankylosing spondylitis
                    who have had an inadequate response to conventional therapy. </item>
                </list>
                <paragraph><content styleCode="bold"><content styleCode="underline">Adult Crohn’s
                      Disease</content></content></paragraph><br/>
                <list listType="unordered">
                  <item>reducing signs and symptoms and inducing and maintaining clinical remission
                    in adult patients with moderately to severely active Crohn’s disease who have
                    had an inadequate response to conventional therapy, including corticosteroids
                    and/or immunosuppressants. HADLIMA<sup>TM</sup> and HADLIMA<sup>TM</sup>
                      PushTouch<sup>TM</sup> are indicated for reducing signs and symptoms and
                    inducing clinical remission in these patients if they have also lost response to
                    or are intolerant to infliximab. </item>
                </list>
                <paragraph><content styleCode="bold"><content styleCode="underline">Ulcerative
                      Colitis</content></content></paragraph><br/>
                <list listType="unordered">
                  <item>treatment of adult patients with moderately to severely active ulcerative
                    colitis (UC) who have had an inadequate response to conventional therapy
                    including corticosteroids and/or azathioprine or 6-mercaptopurine (6-MP) or who
                    are intolerant to such therapies. The efficacy of adalimumab injection in
                    patients who have lost response to or were intolerant to TNF blockers has not
                    been established.</item>
                </list>
                <paragraph><content styleCode="bold"><content styleCode="underline">Hidradenitis
                      Suppurativa</content></content></paragraph><br/>
                <list listType="unordered">
                  <item> treatment of active moderate to severe hidradenitis suppurativa in adult
                    patients, who have not responded to conventional therapy (including systemic
                    antibiotics).</item>
                </list>
                <paragraph><content styleCode="bold"><content styleCode="underline">Plaque
                      Psoriasis</content></content></paragraph><br/>
                <list listType="unordered">
                  <item>treatment of adult patients with chronic moderate to severe plaque psoriasis
                    who are candidates for systemic therapy. For patients with chronic moderate
                    plaque psoriasis, HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                      PushTouch<sup>TM</sup>) should be used after phototherapy has been shown to be
                    ineffective or inappropriate.</item>
                </list>
                <paragraph><content styleCode="bold"><content styleCode="underline">Adult
                      Uveitis</content></content></paragraph><br/>
                <list listType="unordered">
                  <item>treatment of non-infectious uveitis (intermediate, posterior and panuveitis)
                    in adult patients with inadequate response to corticosteroids or as
                    corticosteroid sparing treatment in corticosteroid-dependent patients.</item>
                </list>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <section ID="f2aa7e0e-2042-4a4c-a783-9ad4e8717a32">
                  <id root="b9db4be0-3f06-437a-bd7b-4a3e010adaad"/>
                  <code code="P1-1.1" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="1.1 PEDIATRICS"/>
                  <title>1.1 PEDIATRICS</title>
                  <text>
                    <paragraph><content styleCode="underline">Polyarticular JIA</content><br/>
                      Adalimumab injection has not been studied in pediatric patients with
                      polyarticular JIA less than 2 years of age or in pediatric patients with a
                      weight below 10 kg.<br/><br/> HADLIMA<sup>TM</sup> and HADLIMA<sup>TM</sup>
                        PushTouch<sup>TM</sup> are available for pediatric polyarticular juvenile
                      idiopathic arthritis patients who require the full 40 mg dose based on body
                      weight and height (See <content styleCode="bold">DOSAGE AND
                        ADMINISTRATION</content>, <content styleCode="bold"><content
                          styleCode="underline">Recommended Dosage and Dosage Adjustment,
                          Pediatrics</content></content>, <content styleCode="underline"
                        >Polyarticular Juvenile Idiopathic Arthritis)</content>.<br/><br/> The
                      auto-injector and pre-filled syringe are not designed to deliver a portion of
                      the full 40 mg dose and must not be used in pediatric patients who require
                      &lt; 40 mg dose.</paragraph>
                  </text>
                  <effectiveTime value="20180822"/>
                </section>
              </component>
              <component>
                <section ID="be75cfb9-3132-4903-800b-267427388a13">
                  <id root="b9db4be0-3f46-437a-bd7b-4a3e010adaad"/>
                  <code code="P1-1.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="1.2 GERIATRICS"/>
                  <title>1.2 GERIATRICS</title>
                  <text>
                    <paragraph>Evidence from clinical studies and experience suggests that use of
                      adalimumab injection in the geriatric population is not associated with
                      differences in effectiveness. A brief discussion can be found under (<content
                        styleCode="bold">WARNINGS AND PRECAUTIONS</content>, <content
                        styleCode="bold"><content styleCode="underline">Special
                          Populations</content></content>, <content styleCode="bold">Geriatrics
                        (&gt; 65 years of age))</content>.</paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
            </section>
          </component>
          <component>
            <section ID="be75cfb9-3131-4903-800b-367427388a13">
              <id root="b9db4be0-3f16-437a-bd7b-4a3e010adaad"/>
              <code code="P1-2" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="2 CONTRAINDICATIONS"/>
              <title>2 CONTRAINDICATIONS</title>
              <text>
                <list listType="unordered">
                  <item>HADLIMA<sup>TM</sup> and HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup> are
                    contraindicated in patients who are hypersensitive to this drug or to any
                    ingredient in the formulation, including any non- medicinal ingredient, or
                    component of the container. For a complete listing, see DOSAGE FORMS, STRENGTHS,
                    COMPOSITION AND PACKAGING.</item>
                  <item>Patients with severe infections such as sepsis, tuberculosis and
                    opportunistic infections. See (SERIOUS WARNINGS AND PRECAUTIONS BOX, Serious
                    Warnings and Precautions, Infections).</item>
                  <item>Patients with moderate to severe heart failure (NYHA class III/IV). See
                    (WARNINGS AND PRECAUTIONS, Cardiovascular, Patients with Congestive Heart
                    Failure).</item>
                </list>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="cbe75cfb-3131-4903-800b-267427398a13">
              <id root="b9db4be0-3f46-436a-bd7b-4a3e010adaad"/>
              <code code="P1-3" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="3 SERIOUS WARNINGS AND PRECAUTIONS BOX"/>
              <title>3 SERIOUS WARNINGS AND PRECAUTIONS BOX</title>
              <text>
                <table ID="t1" border="0" cellpadding="1" width="80%">
                  <caption>Serious Warnings and Precautions</caption>
                  <colgroup>
                    <col span="3"/>
                  </colgroup>
                  <tbody>
                    <tr>
                      <td styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content
                            styleCode="underline">Hepatosplenic T-Cell
                        Lymphoma</content></content><br/><br/> Very rare post-marketing reports of
                        hepatosplenic T-cell lymphoma (HSTCL), a rare aggressive lymphoma that is
                        often fatal, have been identified in patients treated with adalimumab
                        injection. Most of the patients had prior infliximab therapy as well as
                        concomitant azathioprine or 6- mercaptopurine use for Crohn’s disease. The
                        potential risk with the combination of azathioprine or 6-mercaptopurine and
                        adalimumab injection should be carefully considered. The causal association
                        of HSTCL with adalimumab injection is not clear.<br/><br/>
                        <content styleCode="bold"><content styleCode="underline"
                            >Infections</content></content><br/><br/> Serious infections due to
                        bacterial, mycobacterial, invasive fungal (disseminated or extrapulmonary
                        histoplasmosis, aspergillosis, coccidiodomycosis), viral, parasitic, or
                        other opportunistic infections have been reported in patients receiving
                        tumor necrosis factor (TNF)- blocking agents. Sepsis, rare cases of
                        tuberculosis, candidiasis, listeriosis, legionellosis and pneumocystis have
                        also been reported with the use of TNF-blocking agents, including adalimumab
                        injection. Other serious infections seen in clinical trials include
                        pneumonia, pyelonephritis, septic arthritis and septicemia. Hospitalization
                        or fatal outcomes associated with infections have been reported. Many of the
                        serious infections have occurred in patients on concomitant
                        immunosuppressive therapy that, in addition to their underlying disease,
                        could predispose them to infections.<br/><br/> Treatment with
                          HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup> )
                        should not be initiated in patients with active infections, including
                        chronic or localized infections, until infections are controlled. In
                        patients who have been exposed to tuberculosis, and patients who have
                        travelled in areas of high risk of tuberculosis or endemic mycoses, such as
                        histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits
                        of treatment with HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                          PushTouch<sup>TM</sup>) should be considered prior to initiating therapy.
                        See (<content styleCode="bold">WARNINGS AND PRECAUTIONS</content>, <content
                          styleCode="bold"><content styleCode="underline"
                          >Infections</content></content>, <content styleCode="bold">Other
                          Opportunistic Infections</content>).<br/><br/> As with other TNF-blockers,
                        patients should be monitored closely for infections (including tuberculosis)
                        before, during and after treatment with HADLIMA<sup>TM</sup> (or
                          HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>).<br/><br/> Patients who
                        develop a new infection while undergoing treatment with HADLIMA<sup>TM</sup>
                        (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) should be monitored closely
                        and undergo a complete diagnostic evaluation. Administration of
                          HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>)
                        should be discontinued if a patient develops a serious infection or sepsis,
                        and appropriate antimicrobial or antifungal therapy should be
                        initiated.<br/><br/> Physicians should exercise caution when considering the
                        use of HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>)
                        in patients with a history of recurrent infection or with underlying
                        conditions which may predispose them to infections, or patients who have
                        resided in regions where tuberculosis and histoplasmosis are endemic. See
                          (<content styleCode="bold">WARNINGS AND PRECAUTIONS</content>, <content
                          styleCode="bold"><content styleCode="underline"
                          >Infections</content></content>, <content styleCode="bold"
                          >Tuberculosis</content>) and (<content styleCode="bold">ADVERSE
                          REACTIONS</content>, <content styleCode="bold"><content
                            styleCode="underline">Adverse Reaction Overview</content></content>,
                          <content styleCode="bold">Infections</content>). The benefits and risks of
                        treatment with HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                          PushTouch<sup>TM</sup>) should be carefully considered before initiating therapy.<br/><br/>
                        <content styleCode="bold"><content styleCode="underline">Pediatric
                            Malignancy</content></content><br/><br/> Lymphoma and other
                        malignancies, some fatal, have been reported in children and adolescent
                        patients treated with TNF-blockers, including adalimumab injection. See
                          (<content styleCode="bold">WARNINGS AND PRECAUTIONS</content>, <content
                          styleCode="bold"><content styleCode="underline"
                          >Malignancies</content></content>, <content styleCode="bold">Malignancies
                          in Pediatric Patients and Young Adults)</content>. </td>
                    </tr>
                  </tbody>
                </table>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="dbe75cfb-3131-4903-800b-267727398a13">
              <id root="b9db4be0-3f46-437a-bd7b-4a3e011adaad"/>
              <code code="P1-4" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="4 DOSAGE AND ADMINISTRATION"/>
              <title>4 DOSAGE AND ADMINISTRATION</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <section ID="be75cfb9-3131-4103-800b-267727398a13">
                  <id root="b9db4be0-3f46-437a-bd7b-4a3e010ddaad"/>
                  <code code="P1-4.1" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="4.1 DOSING CONSIDERATIONS"/>
                  <title>4.1 DOSING CONSIDERATIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="b3d876c1-c36c-4ed5-8993-c507e3ab9f2e">
                  <id root="da2d22a3-b5c2-4a62-b138-9594dd0491bb"/>
                  <code code="P1-4.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT"/>
                  <title>4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-472c-b8a2-a12dba105f3a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-4.3" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="4.3 ADMINISTRATION"/>
                  <title>4.3 ADMINISTRATION</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-472c-b8a2-a12dba105f4a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-4.4" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="4.4 RECONSTITUTION"/>
                  <title>4.4 RECONSTITUTION</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-472c-b8a2-a12dba105f5a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-4.5" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="4.5 MISSED DOSE"/>
                  <title>4.5 MISSED DOSE</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
            </section>
          </component>
          <component>
            <section ID="a63c33a5-e08a-472c-b8a2-a12dba105f6a">
              <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
              <code code="P1-5" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="5 Overdosage"/>
              <title>5 OVERDOSAGE</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="a63c33a5-e08a-472c-b8a2-a12dba105f7a">
              <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
              <code code="P1-6" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING"/>
              <title>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</title>
              <text>
                <paragraph>sample text</paragraph>
                <table ID="t5" border="0" cellpadding="1" width="80%">
                  <caption> Table - Dosage Forms, Strengths, Composition and Packaging</caption>
                  <colgroup>
                    <col span="3"/>
                  </colgroup>
                  <tbody>
                    <tr>
                      <td styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">Route of
                          Administration</content></td>
                      <td styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">Dosage
                          Form / Strength/Composition</content></td>
                      <td styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"
                          >Non-medicinal Ingredients</content></td>
                    </tr>
                    <tr>
                      <td styleCode="Toprule Botrule Lrule Rrule">Subcutaneous injection (s.c.)</td>
                      <td styleCode="Toprule Botrule Lrule Rrule">Sterile solution (in either
                        auto-injector or pre-filled syringe) /40 mg adalimumab injection in 0.8 mL
                        (50 mg/mL)</td>
                      <td styleCode="Toprule Botrule Lrule Rrule">citric acid monohydrate, sodium
                        citrate dihydrate, L-histidine, L-histidine hydrochloride monohydrate,
                        sorbitol, polysorbate 20, and water for injection</td>
                    </tr>
                  </tbody>
                </table>
                <paragraph> HADLIMA<sup>TM</sup> or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>
                  (adalimumab injection) is supplied as a sterile solution for subcutaneous
                  administration in the following packaging configurations:<br/><br/>
                  <content styleCode="bold"><content styleCode="underline"
                    >Auto-injector</content></content><br/><br/> HADLIMA<sup>TM</sup>
                    PushTouch<sup>TM</sup> is available as an auto-injector in a carton containing
                  two dose trays. Each dose tray contains a single-use auto-injector containing a 1
                  mL pre-filled glass syringe with a fixed 29 gauge 1⁄2 inch needle, providing 40 mg
                  of adalimumab injection dissolved in 0.8 mL sterile solution (50 mg/mL). All
                  contents of the auto-injector carton (including auto-injector, accessories and
                  packaging) are latex-free.<br/><br/>
                  <content styleCode="bold"><content styleCode="underline">Pre-Filled
                      Syringe</content></content><br/><br/> HADLIMA<sup>TM</sup> is also available
                  as a pre-filled syringe in a carton containing two dose trays. Each dose tray
                  contains a single-use, 1 mL pre-filled glass syringe with a fixed 29 gauge 1⁄2
                  inch needle, providing 40 mg of adalimumab injection dissolved in 0.8 mL sterile
                  solution (50 mg/mL). All contents of the pre-filled syringe carton (including
                  syringe, accessories and packaging) are latex-free. </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="a63c33a5-e08a-472c-b8a2-a12dba115f7a">
              <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
              <code code="P1-7" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="7 DESCRIPTION"/>
              <title>7 DESCRIPTION</title>
              <text>
                <paragraph>HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>)
                  (adalimumab injection) is a recombinant human immunoglobulin (IgG1) monoclonal
                  antibody. Adalimumab injection has fully human heavy and light chain variable
                  regions, which confer specificity to human tumor necrosis factor (TNF), and human
                  IgG1 heavy chain and kappa light chain sequences. Adalimumab injection binds with
                  high affinity and specificity to soluble tumor necrosis factor (TNF-alpha) but not
                  lymphotoxin (TNF-beta). Adalimumab injection is produced by recombinant DNA
                  technology in a mammalian cell expression system. It consists of 1,330 amino acids
                  and has a molecular weight of approximately 148 kilodaltons.</paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="a63c33a5-e08a-472c-b8a2-a12dba115f8a">
              <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
              <code code="P1-7" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="8 WARNINGS AND PRECAUTIONS"/>
              <title>8 WARNINGS AND PRECAUTIONS</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <section ID="a63c33a5-e08a-472c-b8a2-a12dbc115f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-7.1" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="8.1 SPECIAL POPULATIONS"/>
                  <title>8.1 SPECIAL POPULATIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                  <component>
                    <section ID="da63c33a-e08a-472c-b8a2-b12dbc115f7a">
                      <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                      <code code="P1-7.1.1" codeSystem="2.16.840.1.113883.2.20.6.65"
                        displayName="8.1.1 PREGNANT WOMEN"/>
                      <title>8.1.1 PREGNANT WOMEN</title>
                      <text>
                        <paragraph> sample text </paragraph>
                      </text>
                      <effectiveTime value="20190313"/>
                    </section>
                  </component>
                  <component>
                    <section ID="a63c33a5-e08a-472c-b8a2-b12dbd115f7a">
                      <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                      <code code="P1-7.1.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                        displayName="8.1.2 BREAST-FEEDING"/>
                      <title>8.1.2 BREAST-FEEDING</title>
                      <text>
                        <paragraph> sample text </paragraph>
                      </text>
                      <effectiveTime value="20190313"/>
                    </section>
                  </component>
                  <component>
                    <section ID="a63c33a5-e08a-472c-b8c2-b12dbc115f7a">
                      <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                      <code code="P1-7.1.3" codeSystem="2.16.840.1.113883.2.20.6.65"
                        displayName="8.1.3 PEDIATRICS"/>
                      <title>8.1.3 PEDIATRICS</title>
                      <text>
                        <paragraph> sample text </paragraph>
                      </text>
                      <effectiveTime value="20190313"/>
                    </section>
                  </component>
                  <component>
                    <section ID="a63c33a5-e08a-472c-b8d2-b12dbc115f7a">
                      <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                      <code code="P1-7.1.4" codeSystem="2.16.840.1.113883.2.20.6.65"
                        displayName="8.1.4 GERIATRICS"/>
                      <title>8.1.4 GERIATRICS</title>
                      <text>
                        <paragraph> sample text </paragraph>
                      </text>
                      <effectiveTime value="20190313"/>
                    </section>
                  </component>
                </section>
              </component>
            </section>
          </component>
          <component>
            <section ID="a63c33a5-e08a-472c-b8a2-b22dbc115f7a">
              <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
              <code code="P1-8" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="9 ADVERSE REACTIONS"/>
              <title>9 ADVERSE REACTIONS</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <section ID="a63c63a5-e08a-472c-b8a2-b12dbd215f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-8.1" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="9.1 ADVERSE REACTION OVERVIEW"/>
                  <title>9.1 ADVERSE REACTION OVERVIEW</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-473c-b8a2-b12dbd215f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-8.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="9.2 CLINICAL TRIAL ADVERSE REACTIONS"/>
                  <title>9.2 CLINICAL TRIAL ADVERSE REACTIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c34a5-e08a-473c-b8a2-b12dbd315f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-8.3" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="9.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS"/>
                  <title>9.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-473c-b8a2-b22dbd215f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-8.4" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="9.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC, CLINICAL CHEMISTRY AND OTHER QUANTITATIVE DATA"/>
                  <title>9.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC, CLINICAL CHEMISTRY AND OTHER
                    QUANTITATIVE DATA</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-473c-b8a2-b32dbd215f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-8.5" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="9.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS)"/>
                  <title>9.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS)</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-473c-b8a2-b14dbd215f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-8.6" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="9.6 POST-MARKET ADVERSE REACTIONS"/>
                  <title>9.6 POST-MARKET ADVERSE REACTIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
            </section>
          </component>
          <component>
            <section ID="a63c33a5-e08a-483c-b8a2-b22dbd215f7a">
              <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
              <code code="P1-9" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="10 DRUG INTERACTIONS"/>
              <title>10 DRUG INTERACTIONS</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <section ID="be75cfb9-3131-4903-800b-267527398a13">
                  <id root="b9db4be0-3fa6-437a-bd7b-4a3e010adaad"/>
                  <code code="P1-9.1" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="10.1 SERIOUS DRUG INTERACTIONS BOX"/>
                  <title>10.1 SERIOUS DRUG INTERACTIONS BOX</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-473c-b8a2-b14dbd315f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-9.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="10.2 OVERVIEW"/>
                  <title>10.2 OVERVIEW</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-473c-b8d2-b14dbd315f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-9.3" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="10.3 DRUG-DRUG INTERACTIONS"/>
                  <title>10.3 DRUG-DRUG INTERACTIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e0aa-473c-b8a2-b14dbd315f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-9.4" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="10.4 DRUG-FOOD INTERACTIONSs"/>
                  <title>10.4 DRUG-FOOD INTERACTIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e08a-47bc-b8d2-b14dbd315f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-9.5" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="10.5 DRUG-HERB INTERACTIONS"/>
                  <title>10.5 DRUG-HERB INTERACTIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="be78cfb9-3131-4903-800b-267527398a13">
                  <id root="b93b4be0-3f46-437a-bd7b-4a3e010adaad"/>
                  <code code="P1-9.6" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="10.6 DRUG-LABORATORY TEST INTERACTIONS"/>
                  <title>10.6 DRUG-LABORATORY TEST INTERACTIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="a63c33a5-e0aa-473c-b8a2-b14dcd315f7a">
                  <id root="a473c162-e176-44d0-b797-2b7b6cf00e43"/>
                  <code code="P1-9.7" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="10.7 DRUG-LIFESTYLE INTERACTIONS"/>
                  <title>10.7 DRUG-LIFESTYLE INTERACTIONS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
            </section>
          </component>
          <component>
            <section ID="fa324c26-b939-4c3a-901d-516ccc314522">
              <id root="dc0d2dd9-1c53-49dc-bad3-d6b420d064e9"/>
              <code code="P1-10" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="11 ACTION AND CLINICAL PHARMACOLOGY"/>
              <title>11 ACTION AND CLINICAL PHARMACOLOGY</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <section ID="aa324c26-b939-4c3a-901e-516ccc314522">
                  <id root="dc0d2dd9-1c53-49dc-bad3-d6b420d064e9"/>
                  <code code="P1-10.1" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="11.1 MECHANISM OF ACTION"/>
                  <title>11.1 MECHANISM OF ACTION</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="aa324c26-b939-4d3a-901e-516ccc314522">
                  <id root="ec0d2dd9-1c53-49dc-bad3-d6b420d064e9"/>
                  <code code="P1-10.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="11.2 PHARMACODYNAMICS"/>
                  <title>11.2 PHARMACODYNAMICS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="fa324c26-b939-4d4a-901e-516ccc314522">
                  <id root="dc0d2dd9-1c53-49dc-bad3-d6b420d064e9"/>
                  <code code="P1-10.3" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="11.3 PHARMACOKINETICS"/>
                  <title>11.3 PHARMACOKINETICS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
            </section>
          </component>
          <component>
            <section ID="ca324d26-c939-443a-901e-526dcc314522">
              <id root="ec0d2dd9-1c53-49dc-bad3-d6b420d064e9"/>
              <code code="P1-11" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="12 STORAGE, STABILITY AND DISPOSAL"/>
              <title>12 STORAGE, STABILITY AND DISPOSAL</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="ba325d26-c939-443a-901e-526dcc314522">
              <id root="cc0d2dd9-1c53-49dc-bad3-d6b420d064e9"/>
              <code code="P1-12" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="13 SPECIAL HANDLING INSTRUCTIONS"/>
              <title>13 SPECIAL HANDLING INSTRUCTIONS</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
        </section>
      </component>
      <component>
        <!-- Part II: Scientific Information -->
        <section ID="d6a947eb-e2be-45c0-8b2e-15d0d0eebed8">
          <id root="d91389e0-c234-44d9-8327-91b121723a8f"/>
          <code code="P2" codeSystem="2.16.840.1.113883.2.20.6.65"
            displayName="PART II: SCIENTIFIC INFORMATION"/>
          <title>PART II: SCIENTIFIC INFORMATION</title>
          <effectiveTime value="20190313"/>
          <component>
            <section ID="e3287527-8229-4c12-919e-827854dcd76a">
              <id root="f134d52c-f9d4-4698-a082-84b29ee3d95a"/>
              <code code="P2-13" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="13 Pharmaceutical Information"/>
              <title>14 PHARMACEUTICAL INFORMATION</title>
              <text>
                <table ID="t2" border="0" cellpadding="10" width="80%">
                  <colgroup>
                    <col width="25%" align="left"/>
                  </colgroup>
                  <tbody>
                    <tr>
                      <td valign="top">Proper name:</td>
                      <td>adalimumab injection<br/><br/> Chemical name: Not applicable. Adalimumab
                        injection is not a chemical. It is an immunoglobulin (recombinant human IgG1
                        monoclonal antibody).<br/><br/> Molecular formula and molecular mass:
                        Adalimumab injection consists of 1,330 amino acids and has an apparent
                        molecular weight of approximately 148 kilodaltons (kDa).</td>
                    </tr>
                    <tr>
                      <td valign="top">Chemical Name:</td>
                      <td>Not applicable. Adalimumab injection is not a chemical. It is an
                        immunoglobulin (recombinant human IgG1 monoclonal antibody).<br/><br/>
                        Molecular formula and molecular mass: Adalimumab injection consists of 1,330
                        amino acids and has an apparent molecular weight of approximately 148
                        kilodaltons (kDa).</td>
                    </tr>
                    <tr>
                      <td valign="top">Molecular formula and molecular mass:</td>
                      <td>Adalimumab injection consists of 1,330 amino acids and has an apparent
                        molecular weight of approximately 148 kilodaltons (kDa).</td>
                    </tr>
                    <tr>
                      <td valign="top">Structural formula:</td>
                      <td><renderMultiMedia referencedObject="m1"/></td>
                    </tr>
                    <tr>
                      <td valign="top">Physicochemical properties:</td>
                      <td>HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) is a
                        clear and colorless, sterile, preservative free solution. Each single-dose
                          HADLIMA<sup>TM</sup> and HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>
                        contains a 40 mg/0.8 mL solution of adalimumab injection, with citric acid
                        monohydrate, sodium citrate dihydrate, L-histidine, L-histidine
                        hydrochloride monohydrate, sorbitol, polysorbate 20, and water for
                        injection.</td>
                    </tr>
                    <tr>
                      <td valign="top">Product characteristics:</td>
                      <td>HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>)
                        (adalimumab injection) is a recombinant human immunoglobulin (IgG1)
                        monoclonal antibody specific for human tumor necrosis factor (TNF).
                        Adalimumab injection is an antibody with human derived heavy and light chain
                        variable regions and human IgG1:<sub>k</sub> constant regions. Adalimumab
                        injection is produced by recombinant DNA technology in a mammalian cell
                        expression system and is purified by a process that includes specific viral
                        inactivation and removal steps. It consists of 1,330 amino acids and has a
                        molecular weight of approximately 148 kDa.</td>
                    </tr>
                  </tbody>
                </table>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <observationMedia ID="m1">
                  <text>structure</text>
                  <value xsi:type="ED" mediaType="image/jpeg">
                    <reference value="mab.jpg"/>
                  </value>
                </observationMedia>
              </component>
            </section>
          </component>
          <component>
            <section ID="d3285272-8229-4c12-919e-827854ddd76a">
              <id root="c134d52c-f9d4-4698-a082-84b29ee3d95a"/>
              <code code="P2-14" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="15 COMPARATIVE CLINICAL TRIALS"/>
              <title>15 COMPARATIVE CLINICAL TRIALS</title>
              <text>
                <paragraph> Sample Text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <section ID="e2875272-8229-4c12-919e-827854ddd78a">
                  <id root="c134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                  <code code="P2-14.1" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="15.1 COMPARATIVE TRIAL DESIGN AND STUDY DEMOGRAPHICS"/>
                  <title>15.1 COMPARATIVE TRIAL DESIGN AND STUDY DEMOGRAPHICS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="d4285272-8229-4c12-919e-827854ddd78a">
                  <id root="d134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                  <code code="P2-14.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="15.2 COMPARATIVE STUDY RESULTS"/>
                  <title>15.2 COMPARATIVE STUDY RESULTS</title>
                  <text>
                    <paragraph>Sample Text</paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                  <component>
                    <section ID="f7fcee6a-9032-4542-87c9-c1ef85f89cc5">
                      <id root="d134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                      <code code="P2-14.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                        displayName="15.2.1 COMPARATIVE BIOAVAILABILITY STUDIES"/>
                      <title>15.2.1 COMPARATIVE BIOAVAILABILITY STUDIES</title>
                      <text>
                        <paragraph>Sample Text</paragraph>
                      </text>
                      <effectiveTime value="20190313"/>
                      <component>
                        <section ID="cd0a0cf9-6e8f-4be6-806b-a61f36d22275">
                          <id root="d134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                          <code code="P2-14.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                            displayName="15.2.1.1 PHARMACOKINETICS"/>
                          <title>15.2.1.1 PHARMACOKINETICS</title>
                          <text>
                            <paragraph>Sample Text</paragraph>
                          </text>
                          <effectiveTime value="20190313"/>
                        </section>
                      </component>
                      <component>
                        <section ID="a5058286-7a07-4962-9cf1-b231f113c23a">
                          <id root="b134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                          <code code="P2-14.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                            displayName="15.2.1.2 PHARMACODYNAMICS"/>
                          <title>15.2.1.2 PHARMACODYNAMICS</title>
                          <text>
                            <paragraph>Sample Text</paragraph>
                          </text>
                          <effectiveTime value="20190313"/>
                        </section>
                      </component>
                    </section>
                  </component>
                  <component>
                    <section ID="b590bc92-c8c8-446e-aad6-5e101daf19b9">
                      <id root="f134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                      <code code="P2-14.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                        displayName="15.2.2 COMPARATIVE SAFETY AND EFFICACY"/>
                      <title>15.2.2 COMPARATIVE SAFETY AND EFFICACY</title>
                      <text>
                        <paragraph>Sample Text</paragraph>
                      </text>
                      <effectiveTime value="20190313"/>
                      <component>
                        <section ID="a6d874a7-ad06-4d7a-93f4-a43c87036126">
                          <id root="c134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                          <code code="P2-14.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                            displayName="15.2.2.1 EFFICACY"/>
                          <title>15.2.2.1 EFFICACY</title>
                          <text>
                            <paragraph>Sample Text</paragraph>
                          </text>
                          <effectiveTime value="20190313"/>
                        </section>
                      </component>
                      <component>
                        <section ID="cd273a04-9711-442a-8267-95224bf00483">
                          <id root="a134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                          <code code="P2-14.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                            displayName="15.2.2.2 SAFETYS"/>
                          <title>15.2.2.2 SAFETY</title>
                          <text>
                            <paragraph>Sample Text</paragraph>
                          </text>
                          <effectiveTime value="20190313"/>
                        </section>
                      </component>
                      <component>
                        <section ID="fa8f6ab0-7182-4506-a910-90aca6c84436">
                          <id root="e134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                          <code code="P2-14.2" codeSystem="2.16.840.1.113883.2.20.6.65"
                            displayName="15.2.2.3 IMMUNOGENICITY"/>
                          <title>15.2.2.3 IMMUNOGENICITY</title>
                          <text>
                            <paragraph>Sample Text</paragraph>
                          </text>
                          <effectiveTime value="20190313"/>
                        </section>
                      </component>
                    </section>
                  </component>
                </section>
              </component>
              <component>
                <section ID="e4285272-8229-4c12-919e-827954ddd78a">
                  <id root="b134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                  <code code="P2-14.3" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="15.3 COMPARATIVE BIOAVAILABILITY STUDIES"/>
                  <title>15.3 COMPARATIVE BIOAVAILABILITY STUDIES</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
            </section>
          </component>
          <component>
            <section ID="a2875272-8229-4c12-a19e-827954ddd78a">
              <id root="d134d52c-f9d4-4698-a082-84b29ee3d95a"/>
              <code code="P2-15" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="16 COMPARATIVE NON-CLINICAL PHARMACOLOGY AND TOXICOLOGY"/>
              <title>16 COMPARATIVE NON-CLINICAL PHARMACOLOGY AND TOXICOLOGY</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
              <component>
                <section ID="d49e689f-111c-4ef8-bb69-c68d02665d8a">
                  <id root="d134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                  <code code="P2-15" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="16.1 COMPARATIVE NON-CLINICAL PHARMACODYNAMICS"/>
                  <title>16.1 COMPARATIVE NON-CLINICAL PHARMACODYNAMICS</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
              <component>
                <section ID="c49b8074-0cff-4d2d-bfc0-ce07f2f47bc3">
                  <id root="a134d52c-f9d4-4698-a082-84b29ee3d95a"/>
                  <code code="P2-15" codeSystem="2.16.840.1.113883.2.20.6.65"
                    displayName="16.2 COMPARATIVE TOXICOLOGY"/>
                  <title>16.2 COMPARATIVE TOXICOLOGY</title>
                  <text>
                    <paragraph> sample text </paragraph>
                  </text>
                  <effectiveTime value="20190313"/>
                </section>
              </component>
            </section>
          </component>
          <component>
            <section ID="d42a7527-8229-4c12-a19e-827954ddd78a">
              <id root="c134d52c-f9d4-4698-a082-84b29ee3d95a"/>
              <code code="P2-16" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="17 NON-CLINICAL TOXICOLOGY"/>
              <title>17 CLINICAL TRIALS - REFERENCE BIOLOGIC DRUG</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="b8a4d498-0fc3-4e44-b4b6-550140d4de5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P2-17" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="18 NON-CLINICAL TOXICOLOGY - REFERENCE BIOLOGIC DRUG"/>
              <title>18 NON-CLINICAL TOXICOLOGY - REFERENCE BIOLOGIC DRUG</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="e2ab1d1d-17ac-4ee9-a432-dd8f06a958e4">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P2-17" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="18 NON-CLINICAL TOXICOLOGY - REFERENCE BIOLOGIC DRUG"/>
              <title>19 SUPPORTING PRODUCT MONOGRAPHS</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
        </section>
      </component>
      <component>
        <!-- Part III: Patient Medication Information -->
        <section ID="baa4d498-0fc3-4e44-b4b6-550140d4de5d">
          <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
          <code code="P3" codeSystem="2.16.840.1.113883.2.20.6.65"
            displayName="Part III: Patient Medication Information"/>
          <title>PART III: PATIENT MEDICATION INFORMATION</title>
          <effectiveTime value="20190313"/>
          <component>
            <section ID="baa4d498-0fc3-4e44-b4b6-550140dde5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-1" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="BRAND NAME"/>
              <title>BRAND NAME</title>
              <text>
                <paragraph>HADLIMA<sup>TM</sup> (pronounced) &lt; HAD-lee-mah &gt; Adalimumab injection 40
                  mg/0.8 mL subcutaneous injection (Pre-filled syringe) HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>
                  Adalimumab injection 40 mg/0.8 mL subcutaneous injection
                  (Auto-injector)</paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="daa40d49-0fc3-4e44-b4b6-550140d4e5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-2" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="PROPER NAME IN FINAL DOSAGE FORM"/>
              <title>PROPER NAME IN FINAL DOSAGE FORM</title>
              <text>
                <paragraph>Read this carefully before you/your child start taking HADLIMA<sup>TM</sup> (or
                  HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) and each time you/your child get a refill. This leaflet is
                  a summary and will not tell you/your child everything about this drug. Talk to
                  your/your child’s healthcare professional about your/your child’s medical
                  condition and treatment and ask if there is any new information about HADLIMA<sup>TM</sup>
                  (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>).<br/><br/> HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) is a
                  biosimilar biologic drug (biosimilar) to the reference biologic drug Humira®. A
                  biosimilar is authorized based on its similarity to a reference biologic drug that
                  was already authorized for sale.</paragraph>
                <table ID="t3" width="80%">
                  <caption>Serious Warnings and Precautions</caption>
                  <tbody>
                    <tr>
                      <td><paragraph>Before starting, during and after treatment with HADLIMA<sup>TM</sup> (or
                          HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>), you/your child should be checked for active or
                          inactive tuberculosis infection with a tuberculin skin test. Any medicine
                          can have side effects. Like all medicines that affect your/your child’s
                          immune system, HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) can cause serious side
                          effects. The possible serious side effects include:<br/><br/></paragraph>
                        <list>
                          <item><content styleCode="bold"><content styleCode="underline">Allergic
                                reactions:</content></content> If you/your child develop a severe
                            rash, swollen face or difficulty breathing while taking HADLIMA<sup>TM</sup> (or
                            HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>), call your/your child’s doctor right away.
                          </item>
                        </list>
                        <list>
                          <item><content styleCode="bold"><content styleCode="underline"
                                >Hepatosplenic T-cell lymphoma:</content></content> Very rare
                            reports of hepatosplenic T-cell lymphoma (HSTCL), a rare serious
                            lymphoma that is often fatal, have been identified in patients treated
                            with adalimumab injection. Most patients had also been treated with
                            other medications for Crohn’s disease and the majority were in
                            adolescent and young adult males. The link between HSTCL and adalimumab
                            injection is not clear.</item>
                        </list>
                        <list>
                          <item><content styleCode="bold"><content styleCode="underline">Other
                                cancers:</content></content> There have been very rare cases of
                            certain kinds of cancer in patients taking adalimumab injection or other
                            TNF-blockers. Some patients receiving adalimumab injection have
                            developed types of cancer called non-melanoma skin cancer. Tell
                            your/your child’s doctor if you/your child have a bump or open sore that
                            does not heal. People with more serious rheumatoid arthritis that have
                            had the disease for a long time may have a higher than average risk of
                            getting a kind of cancer that affects the lymph system, called lymphoma.
                            If you/your child take HADLIMA<sup>TM</sup>, HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>, or other TNF-
                            blockers, your/your child’s risk may increase. There have been cases of
                            lymphoma and other cancers, including unusual types, in children,
                            adolescents and young adults taking TNF-blocking agents, including
                            adalimumab injection, which sometimes resulted in death. For children
                            and adults taking TNF-blocker medicines, the chances of developing
                            lymphoma or other cancers may increase.</item>
                        </list>
                        <list>
                          <item><content styleCode="bold"><content styleCode="underline">Lupus-like
                                symptoms:</content></content> Some patients have developed
                            lupus-like symptoms that got better after their treatment was stopped.
                            If you/your child have chest pains that do not go away, shortness of
                            breath, joint pain or a rash on your/your child’s cheeks or arms that
                            gets worse in the sun, call your/your child’s doctor right away.
                            Your/your child’s doctor may decide to stop your/your child’s
                            treatment.</item>
                        </list>
                        <list>
                          <item><content styleCode="bold"><content styleCode="underline">Nervous
                                system diseases:</content></content> There have been rare cases of
                            disorders that affect the nervous system of people taking adalimumab
                            injection or other TNF-blockers. Signs that you/your child could be
                            experiencing a problem affecting your/your child’s nervous system
                            include: numbness or tingling, problems with your/your child’s vision,
                            weakness in your/your child’s legs, and dizziness.</item>
                        </list>
                        <list>
                          <item><content styleCode="bold"><content styleCode="underline">Serious
                                infections:</content></content> There have been rare cases where
                            patients taking adalimumab injection or other TNF-blocking agents have
                            developed serious infections. Some of these cases have been
                            life-threatening. Such infections include tuberculosis, infections
                            caused by bacteria or fungi, and bacterial infections that have spread
                            throughout the body (sepsis). Infection causes include tuberculosis,
                            legionellosis (a serious form of bacterial pneumonia), listeriosis (an
                            infection that usually develops after eating food contaminated by
                            bacteria called listeria), and very rare cases of hepatitis B infection
                            relapse.</item>
                        </list>
                        <list>
                          <item><content styleCode="bold"><content styleCode="underline">Blood
                                problems:</content></content> In some instances, patients treated
                            with TNF-blocking agents may develop low blood counts, such as anemia
                            (low red blood cells) or low platelets. If you/your child develop
                            symptoms such as persistent fever, bleeding, or bruising, you should
                            contact your/your child’s doctor right away</item>
                        </list>
                      </td>
                    </tr>
                  </tbody>
                </table>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="baa4d498-08c3-4e44-bcb6-550140d4de5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-3" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="WHAT IS THIS MEDICATION USED FOR?"/>
              <title>WHAT IS THIS MEDICATION USED FOR?</title>
              <text>
                <paragraph>HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) treatment should be started and
                  supervised by specialist physicians experienced in the diagnosis and treatment of
                  rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA),
                  psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn’s disease
                  (CD), ulcerative colitis (UC), adult hidradenitis suppurativa (HS), psoriasis (Ps)
                  or adult uveitis, and familiar with the HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>)
                  efficacy and safety profile.<br/><br/> HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) is a
                  medicine that is used in:</paragraph>
                <list>
                  <item>adults with rheumatoid arthritis, which is an inflammatory disease of the
                    joints.</item>
                  <item>adults with psoriatic arthritis, which is an inflammatory disease of the
                    joints and skin.</item>
                  <item>adults with ankylosing spondylitis, which is a form of arthritis.</item>
                  <item>adults with Crohn’s disease, which is an inflammatory disease of the
                    digestive tract.</item>
                  <item>pediatrics with polyarticular juvenile idiopathic arthritis who are 4 years
                    of age and older and require a full 40 mg dose based on body weight and
                    height.</item>
                  <item>adults with ulcerative colitis, which is an inflammatory disease of the
                    bowel (colon).</item>
                  <item>adults with moderate to severe hidradenitis suppurativa (HS) who have not
                    responded to antibiotics. HS is a painful, progressive, chronic inflammatory
                    skin disease that causes nodules, abscesses, sinus tracts and fistulas under the
                    breasts, underarms, buttocks and groin.</item>
                  <item>adults with psoriasis, which is an inflammatory disease of the skin. The
                    doctor prescribed HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) to reduce the signs and
                    symptoms of your plaque psoriasis.</item>
                  <item>adults with uveitis, which is an inflammatory disease of the eye.</item>
                </list>
                <paragraph> Patients with rheumatoid arthritis, polyarticular juvenile idiopathic
                  arthritis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa,
                  psoriasis, or uveitis may be given other medicines for their disease before they
                  are given HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>). If you have ulcerative colitis or
                  Crohn’s disease, you will first be given other medicines. If you do not respond
                  well enough to these medicines, you will be given HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                  PushTouch<sup>TM</sup>) to reduce the signs and symptoms of your disease. </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="bca4d498-0gc3-4e44-bcb6-550140d4de5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-4" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="HOW DOES THIS MEDICATION WORK?"/>
              <title>HOW DOES THIS MEDICATION WORK?</title>
              <text>
                <paragraph>HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) is a fully human monoclonal antibody
                  produced by cultured cells. Monoclonal antibodies are proteins that recognize and
                  bind to other unique proteins. HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) binds to a
                  specific protein called TNF- alpha (also known as tumor necrosis factor). People
                  with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s
                  disease, ulcerative colitis, hidradenitis suppurativa or psoriasis have too much
                  of TNF-alpha in their bodies. The extra TNF-alpha in your/your child’s body can
                  attack normal healthy body tissues and cause inflammation, especially in the
                  tissues of your /your child’s bones, cartilage, joints, digestive tract and skin.
                  By binding to TNF-alpha, HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) decreases the
                  inflammation process of these diseases.<br/><br/> HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                  PushTouch<sup>TM</sup>) helps reduce the signs and symptoms of rheumatoid arthritis,
                  polyarticular juvenile idiopathic arthritis and psoriatic arthritis (such as pain
                  and swollen joints), may help improve your/your child’s ability to perform daily
                  activities (such as getting dressed, walking and climbing stairs), and may help
                  prevent further damage to your/your child’s bones and joints. In addition,
                  HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) helps reduce the signs and symptoms of
                  ankylosing spondylitis (back pain and morning stiffness), and adult Crohn’s
                  disease or ulcerative colitis (abdominal pain and diarrhea).<br/><br/> HADLIMA<sup>TM</sup>
                  (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) is also used to treat inflammatory lesions (nodules and
                  abscesses) in adult patients with hidradenitis suppurativa.<br/><br/> HADLIMA<sup>TM</sup>
                  (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) also helps reduce the signs and symptoms of psoriasis
                  (such as pain, itching and scaly patches on skin).<br/><br/> HADLIMA<sup>TM</sup> (or
                  HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) helps control uveitis by reducing the risk of inflammation
                  and loss of vision in adult patients.<br/><br/> HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                  PushTouch<sup>TM</sup>), however, can also lower your/your child’s body’s ability to fight
                  infections. Taking HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) can make you/your child
                  more prone to getting infections or make any infection you/your child have
                  worse.<br/><br/>
                </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="bca4d498-0gc3-4e44-bcb6-55013024de5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-5" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="WHAT ARE THE INGREDIENTS IN THIS MEDICATION?"/>
              <title>WHAT ARE THE INGREDIENTS IN THIS MEDICATION?</title>
              <text>
                <paragraph>Medicinal ingredients: adalimumab injection<br/> Non-medicinal
                  ingredients: citric acid monohydrate, sodium citrate dihydrate, L-histidine, L-
                  histidine hydrochloride monohydrate, sorbitol, polysorbate 20, water for
                  injection</paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="bca4d498-0gc3-4e54-bcb6-550130d4de5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-6" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:"/>
              <title>THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:</title>
              <text>
                <list>
                  <item>Single-use, 1 mL auto-injector containing 40 mg adalimumab injection
                    dissolved in 0.8 mL sterile solution (50 mg/mL)</item>
                  <item>Single-use, 1 mL pre-filled glass syringe containing 40 mg adalimumab
                    injection dissolved in 0.8 mL sterile solution (50 mg/mL)</item>
                </list>
                <paragraph> All packaging components are latex-free.</paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="bca4c498-0gc3-4e44-bcb6-550134d4de5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-7" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="DO NOT USE THIS MEDICATION IF:"/>
              <title>DO NOT USE THIS MEDICATION IF:</title>
              <text>
                <paragraph>You/your child should not take HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) if
                  you/your child have:</paragraph>
                <list>
                  <item>an allergy to any of the ingredients in HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>)
                    (see <content styleCode="bold">What are the ingredients in HADLIMA<sup>TM</sup> (or
                      HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>)</content>? section).</item>
                  <item>a serious infection such as tuberculosis, infections caused by bacteria or
                    fungi, and bacterial infections that have spread throughout the body
                    (sepsis).</item>
                  <item>moderate to severe heart failure (NYHA class III/IV).</item>
                </list>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="b6b37351-bbc9-46d9-b148-27ba3cb0a75e">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-8" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE THIS MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU:"/>
              <title>TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE
                PROFESSIONAL BEFORE YOU TAKE THIS MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR
                PROBLEMS YOU MAY HAVE, INCLUDING IF YOU:</title>
              <text>
                <list>
                  <item>you/your child have or have had any kind of infection including an infection
                    that is in only one place in your/your child’s body (such as an open cut or
                    sore), or an infection that is in your/your child’s whole body (such as the
                    flu). Having an infection could put you/your child at risk for serious side
                    effects from HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>). If you are unsure, ask
                    your/your child’s doctor.</item>
                  <item>you/your child have a history of infections that keep coming back or other
                    conditions that might increase your/your child’s risk of infections, including
                    fungal infections.</item>
                  <item>you/your child have ever had tuberculosis, or if you/your child have been in
                    close contact with someone who has had tuberculosis. If you/your child develop
                    any of the symptoms of tuberculosis (a dry cough that doesn't go away, weight
                    loss, fever, night sweats) call your/your child’s doctor right away. Your/your
                    child’s doctor will need to examine you/your child for tuberculosis and perform
                    a skin test.</item>
                  <item>you/your child resided or travelled to areas where there is a greater risk
                    for certain kinds of infections such as tuberculosis, histoplasmosis,
                    coccidioidomycosis, blastomycosis, or parasitic infections. These infections are
                    caused by a bacteria or a fungus that can affect the lungs or other parts of
                    your/your child’s body. If you/your child take HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                    PushTouch<sup>TM</sup>) these may become active or more severe. If you don’t know if
                    you/your child have lived in or travelled to an area where these infections are
                    common, ask your/your child’s doctor.</item>
                  <item>you/your child have ever had liver injury or hepatitis B virus infection or
                    are at risk of developing this infection. Signs and symptoms include the
                    following: yellowing of the skin or eyes (jaundice), feeling of sickness,
                    tiredness, loss of appetite, joint pain, fever, dark brown-colored urine,
                    vomiting, and abdominal pain. If you/your child experience any of these signs
                    and symptoms, contact your/your child’s doctor immediately. These symptoms may
                    occur several months after starting therapy with HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                    PushTouch<sup>TM</sup>).</item>
                  <item>you/your child experience any numbness or tingling or have ever had a
                    disease that affects your/your child’s nervous system like multiple sclerosis or
                    Guillain-Barré syndrome.</item>
                  <item>you/your child have or have had heart failure.</item>
                  <item>you/your child are scheduled to have major surgery or dental
                    procedures.</item>
                  <item>you/your child are scheduled to be vaccinated for anything. It is
                    recommended that pediatric patients, if possible, be brought up to date with all
                    immunizations according to current guidelines before starting HADLIMA<sup>TM</sup> (or
                    HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>).</item>
                  <item>you/your child are taking other medicines for your/your child’s rheumatoid
                    arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis,
                    ankylosing spondylitis, Crohn’s disease, psoriasis, or other conditions.
                    You/your child can take other medicines provided your/your child’s doctor has
                    prescribed them or has told you/your child it is acceptable that you/your child
                    take them while you/your child are taking HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>).
                    It is important that you tell your/your child’s doctor about any other medicines
                    you/your child are taking for other conditions (for example, high blood pressure
                    medicine) before you/your child start taking HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                    PushTouch<sup>TM</sup>).</item>
                  <item>you/your child are taking any over-the-counter drugs, herbal medicines and
                    vitamin and mineral supplements.</item>
                  <item>you/your child are pregnant or could become pregnant</item>
                  <item>you/your child are breast-feeding or plan to breast-feed.</item>
                </list>
                <paragraph><content styleCode="bold"><content styleCode="italics">If you/your child
                      are not sure or have any questions about any of this information, ask
                      your/your child’s doctor.</content></content></paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="edac0d6f-3c91-48b5-99c0-e0f940925d37">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-9" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="OTHER WARNINGS YOU SHOULD KNOW ABOUT:"/>
              <title>OTHER WARNINGS YOU SHOULD KNOW ABOUT:</title>
              <text>
                <paragraph>If you/your child received HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) while
                  pregnant, your/her baby may be at higher risk for getting an infection for up to
                  approximately five months after the last dose of HADLIMA<sup>TM</sup> (or HADLIMA<sup>TM</sup>
                  PushTouch<sup>TM</sup>) received during pregnancy. It is important that you/she tell your/her
                  baby's doctors and other healthcare professionals about your/her HADLIMA<sup>TM</sup> (or
                  HADLIMA<sup>TM</sup> PushTouch<sup>TM</sup>) use during pregnancy so they can decide when your/her baby
                  should receive any vaccine.</paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="f040bb1e-8989-42c8-82dc-53a855e88f0f">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-10" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES"/>
              <title>TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING
                ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="bca4c498-0ec3-4e44-bcb6-550134d4de5d">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-11" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="THE FOLLOWING MAY INTERACT WITH THIS MEDICATION:"/>
              <title>THE FOLLOWING MAY INTERACT WITH THIS MEDICATION:</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="e23321cd-5111-4aa3-b650-74f93bcda261">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-12" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="HOW TO TAKE THIS MEDICATION:"/>
              <title>HOW TO TAKE THIS MEDICATION:</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="cd0892a2-0e32-4fb7-9cc9-1bbfff60dee7">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-13" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="USUAL DOSE:"/>
              <title>USUAL DOSE:</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="beaaa5b8-6693-4d4c-a897-fa5c9562b1be">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-14" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="OVERDOSE:"/>
              <title>OVERDOSE:</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="ffd59b8d-fe66-4d86-a54f-0613d4168199">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-15" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="MISSED DOSE:"/>
              <title>MISSED DOSE:</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="cb61f530-b95a-4047-b8ea-861c5a7a05e8">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-16" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION?"/>
              <title>WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION?</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="ee37dfa5-6d8c-4490-b4a5-c6f2d73aa041">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-17" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM"/>
              <title>SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="fc829574-2519-45eb-b534-7553da2270ed">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-17" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="REPORTING SIDE EFFECTS"/>
              <title>REPORTING SIDE EFFECTS</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="c9d75711-2ce9-451e-aa51-91026ec1555e">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-18" codeSystem="2.16.840.1.113883.2.20.6.65" displayName="STORAGE:"/>
              <title>STORAGE:</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
          <component>
            <section ID="f6693e7a-21c9-492f-833b-4e8f3911d3a5">
              <id root="be74b6e6-c431-4a5f-a18e-ed321b381456"/>
              <code code="P3-19" codeSystem="2.16.840.1.113883.2.20.6.65"
                displayName="IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:"/>
              <title>IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:</title>
              <text>
                <paragraph> sample text </paragraph>
              </text>
              <effectiveTime value="20190313"/>
            </section>
          </component>
        </section>
      </component>
    </structuredBody>
  </component>
</document>
